Back to Results
First PageMeta Content
Medicine / Cardiology / Lipoproteins / Lysosomal Acid Lipase Deficiency / Clinical research / Cholesteryl ester storage disease / Wolman disease / Niacin / Clinical trial / Health / Rare diseases / Lipid storage disorders


SYNAGEVA BIOPHARMA™ REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LAL DEFICIENCY Phase 3 Study Meets Primary Endpoint and Six Secondary Endpoints Across Multiple Di
Add to Reading List

Document Date: 2014-10-09 07:26:12

Open Document

File Size: 312,69 KB

Share Result on Facebook

City

LEXINGTON / /

Company

Synageva BioPharma Corp. / /

/

Event

Conference Call / FDA Phase / /

IndustryTerm

biopharmaceutical company developing therapeutic products / imaging / /

MedicalCondition

abdominal pain / rare diseases / disease / atherosclerosis / headache / nasopharyngitis / nausea / Dyslipidemia / lysosomal acid lipase deficiency / cirrhosis / Cholesteryl Ester Storage Disease / Wolman disease / diseases / lysosomal storage disease / liver injury / constipation / LAL Deficiency / Fibrosis / /

MedicalTreatment

enzyme replacement therapy / /

Organization

FDA / Ministry of Health / /

Person

Anthony Quinn / Sanj K. Patel / Matthew Osborne / /

/

Position

President and Chief Executive Officer / Executive Vice President and Chief / forward / Officer / /

Product

SEBELIPASE ALFA IN / /

ProvinceOrState

Massachusetts / /

Technology

magnetic resonance imaging / MRI / /

URL

www.synageva.com / /

SocialTag